Amarin Co. plc (NASDAQ:AMRN) Forecasted to Post Q2 2025 Earnings of ($0.06) Per Share

Amarin Co. plc (NASDAQ:AMRN) – Research analysts at Zacks Research decreased their Q2 2025 earnings per share estimates for shares of Amarin in a note issued to investors on Tuesday, April 30th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings per share of ($0.06) for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Amarin’s current full-year earnings is ($0.14) per share. Zacks Research also issued estimates for Amarin’s Q1 2026 earnings at ($0.05) EPS.

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $1.08.

Amarin Stock Performance

NASDAQ AMRN opened at $0.91 on Friday. Amarin has a 52-week low of $0.65 and a 52-week high of $1.49. The company has a fifty day moving average of $0.95 and a 200-day moving average of $0.94. The company has a market capitalization of $373.71 million, a P/E ratio of -7.58 and a beta of 1.96.

Amarin (NASDAQ:AMRN) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.02. The business had revenue of $56.52 million during the quarter, compared to analyst estimates of $51.34 million. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.43%. During the same period in the previous year, the business posted ($0.04) earnings per share.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in AMRN. GSA Capital Partners LLP boosted its stake in shares of Amarin by 74.4% in the 1st quarter. GSA Capital Partners LLP now owns 1,482,540 shares of the biopharmaceutical company’s stock valued at $1,321,000 after purchasing an additional 632,497 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Amarin by 104.8% during the first quarter. BNP Paribas Financial Markets now owns 932,173 shares of the biopharmaceutical company’s stock valued at $830,000 after buying an additional 476,996 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in Amarin by 66.3% during the first quarter. China Universal Asset Management Co. Ltd. now owns 74,178 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 29,579 shares during the period. Newbridge Financial Services Group Inc. purchased a new position in shares of Amarin in the first quarter worth about $37,000. Finally, Simplicity Wealth LLC purchased a new position in shares of Amarin in the first quarter worth about $418,000. 22.25% of the stock is owned by hedge funds and other institutional investors.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.